Rosetta Genomics Ltd. (ROSGQ)

Market Cap	593.00
Revenue (ttm)	2.86M
Net Income (ttm)	-13.39M
Shares Out	5.93M
EPS (ttm)	-6.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,036
Average Volume	4,048
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	56.98
RSI	92.92
Earnings Date	n/a

About Blueprint Medicines

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company’s microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 86
• Stock Exchange: OTCMKTS
• Ticker Symbol: ROSGQ

Financial Performance

In 2016, Rosetta Genomics's revenue was $2.04 million, a decrease of -29.08% compared to the previous year's $2.88 million. Losses were -$16.23 million, -6.41% less than in 2015.